Monopar's pipeline includes clinical-stage
radiopharmaceuticals targeting advanced solid tumors and late-stage
ALXN1840, a treatment for Wilson Disease
NORTH
CHICAGO, Ill., Jan. 23,
2025 /PRNewswire/ -- Rosalind
Franklin University of Medicine and Science announced that
Monopar Therapeutics is the latest biotech company to join the
Helix 51 biomedical incubator community.
Monopar, a clinical-stage biotechnology firm, is developing
personalized and precise radiopharmaceuticals to diagnose and treat
aggressive cancers, and will utilize the labs and other resources
in Helix 51 to further its research objectives.
"We are excited to be a part of the vibrant biomedical community
at RFU," said Monopar COO Andrew
Cittadine, MBA. "We see this as an opportunity to accelerate
the development of new products and were drawn to the talented and
collaborative community at Helix 51."
Radiopharmaceuticals — drugs that selectively target cancer and
are linked with radioisotopes — are a key component of nuclear
medicine. Rapid advancements in the field have significantly
improved healthcare by enabling highly targeted diagnosis and
treatment of diseases, particularly cancer, through the precise
delivery of radiation directly to diseased tissues. The technique
helps minimize damage to healthy organs, leading to earlier
detection, more effective therapies and improved patient outcomes
with fewer side effects.
An article published this month in the journal Signal
Transduction and Targeted Therapy hailed the technology's
ability to "improve the efficiency and biosafety of tumour
diagnosis and therapy."
Monopar is also working on a late-stage investigational drug for
the treatment of Wilson Disease, a rare genetic disorder.
Helix 51 is the only wet-and dry-lab based incubator in
Lake County, Illinois, which is
home to more than 122 bioscience companies and 33,000 bioscience
jobs. The university's Innovation and Research Park also provides
research space to biotech and biopharma companies looking to grow.
The IRP features numerous core facilities essential for drug,
device and diagnostic research and development.
"Rosalind Franklin University is
committed to expanding collaboration between academic research and
the life-science industry to develop new therapeutic solutions for
difficult-to-treat diseases," said Dr. Joseph DiMario, RFU interim vice president for
research. "Our Center for Cancer Cell Biology, Immunology, and
Infection and Center for Genetic Diseases can also
provide additional research support and expertise to Monopar. We're
pleased to include them in our growing oncology cluster of
companies."
About Rosalind Franklin
University
Rosalind Franklin
University of Medicine and Science is committed to serving
humanity through the interprofessional education of health and
biomedical professionals and the discovery of knowledge dedicated
to improving wellness. The university embodies the spirit of
inquiry and excellence modeled by its namesake Dr. Rosalind Franklin, whose Photo 51 was crucial to
solving the structure of DNA. Recognized for its research in areas
including neuroscience, brain-related diseases, inherited
disorders, diabetes, obesity, and gait and balance, RFU encompasses
the Chicago Medical School, College of Health Professions, College
of Nursing, College of Pharmacy, School of Graduate and
Postdoctoral Studies and the Dr. William M.
Scholl College of Podiatric Medicine. Learn more at
rosalindfranklin.edu.
Office of Marketing and
Communications
media@rosalindfranklin.edu
View original content to download
multimedia:https://www.prnewswire.com/news-releases/rosalind-franklin-universitys-helix-51-incubator-welcomes-monopar-therapeutics-302358955.html
SOURCE Rosalind Franklin University of
Medicine and Science
